Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.57 |
| ▸ | HINT1 | P49773 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18950667 | 1.00 | ADORA2A (0.57) | ADORA2AADORA2BHINT1ADORA3ADORA1 | |
| SCHEMBL24943257 | 0.89 | ADORA2A (0.55) | ADORA2AADORA2BHINT1ADORA3ADORA1 | |
| SCHEMBL16801790 | 0.88 | ADORA1 (0.67) | ADORA2AADORA2BADORA3ADORA1HIF1A | |
| SCHEMBL2402156 | 0.88 | ADORA1 (0.67) | ADORA2AADORA2BADORA3ADORA1HIF1A | |
| SCHEMBL2402159 | 0.88 | ADORA1 (0.67) | ADORA2AADORA2BADORA3ADORA1HIF1A | |
| SCHEMBL15993868 | 0.87 | ADORA2A (0.57) | ADORA2AADORA2BHINT1ADORA3ADORA1 | |
| SCHEMBL7608233 | 0.87 | ADORA2A (0.61) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL3624008 | 0.87 | ADORA2A (0.61) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL1527213 | 0.86 | ADORA2A (0.66) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL12150807 | 0.86 | ADORA2A (0.66) | ADORA2AADORA2BADORA3ADORA1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9463200-B2 | Cell-penetrating oligonucleotides | OLIGOMER SCIENCES AB (SE) | 2016-10-11 | — | — | US | disclosed |
| US-9463200-B2 | Cell-penetrating oligonucleotides | OLIGOMER SCIENCES AB (SE) | 2016-10-11 | — | — | US | disclosed |
| US-20160008389-A1 | Cell-Penetrating Oligonucleotides | ASTRAZENECA AB (SE) | 2016-01-14 | — | — | US | disclosed |
| US-20160008389-A1 | Cell-Penetrating Oligonucleotides | ASTRAZENECA AB (SE) | 2016-01-14 | — | — | US | disclosed |
| WO-2014131892-A1 | CELL-PENETRATING OLIGONUCLEOTIDES | OLIGOMER SCIENCES AB (SE) | 2014-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008389-A1 | Cell-Penetrating Oligonucleotides | SLC29A1, SLC29A2, TYMP | ADORA2A 28/4885ADORA2B 37/4885HINT1 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.